1.60Open2.70Pre Close19 Volume176 Open Interest22.50Strike Price3.04KTurnover140.36%IV2.51%PremiumDec 20, 2024Expiry Date1.01Intrinsic Value100Multiplier5DDays to Expiry0.59Extrinsic Value100Contract SizeAmericanOptions Type0.6367Delta0.0953Gamma11.20Leverage Ratio-0.1509Theta0.0018Rho7.13Eff Leverage0.0105Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet